Literature DB >> 6994776

Elimination of guanfacine in patients with normal and impaired renal function.

W Kirch, H Köhler, W Braun.   

Abstract

1. Total body clearance and renal clearance after single intravenous doses of guanfacine were 360 +/- 262 (mean +/- s.d.) and 233 +/- 245 ml/min, respectively, in patients with normal renal function (glomerular filtration rate (GFR) > 90 ml/min), 308 +/- 274 and 34 +/- 22 ml/min, respectively, in patients with moderately impaired renal function (GFR 30-10 ml/min), and 257 +/- 187 and 18 +/- 15 ml/min, respectively, in preuremic patients (GFR < 10 ml/min). 2. The cumulative urinary excretion up to 48 h after a single intravenous injection of guanfacine was 57.0 +/- 32.0% in patients with GFR > 90 ml/min, 14.0 +/- 9.0% in patients with GFR 30-10 ml/min and 7.5 +/- 2.4% in preuremic patients. 3. In normal as well as impaired renal function the elimination rate constant of guanfacine was 0.05 h-1, which corresponds to an elimination half-life of 14 h, independent of renal function. 4. These results suggest that non-renal elimination of guanfacine plays an important role in patients with renal failure. 5. Intestinal absorption of guanfacine was calculated to be 59 +/- 19% in patients with GFR > 90 ml/min, to 68 +/- 16% in patients with GFR 30-10 ml/min, and to 73 +/- 36% in preuremic patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6994776      PMCID: PMC1430110          DOI: 10.1111/j.1365-2125.1980.tb04902.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Pharmacology of BS 100-141, a centrally acting antihypertensive drug.

Authors:  K Saameli; G Scholtysik; R Waite
Journal:  Clin Exp Pharmacol Physiol       Date:  1975       Impact factor: 2.557

2.  The influence of renal function on plasma levels, urinary excretion, metabolism, and antihypertensive effect of guanethidine (ismelin) in man.

Authors:  K H Rahn
Journal:  Clin Nephrol       Date:  1973 Jan-Feb       Impact factor: 0.975

3.  [First experiences with BS 100-141, a new antihypertensive substance].

Authors:  I Esch
Journal:  Int J Clin Pharmacol Biopharm       Date:  1976-09

4.  Substituted phenylacetylguanidines: a new class of antihypertensive agents.

Authors:  J B Bream; H Lauener; C W Picard; G Scholtysik; T G White
Journal:  Arzneimittelforschung       Date:  1975-10

5.  Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141).

Authors:  G Scholtysik; H Lauener; E Eichenberger; H Bürki; R Salzmann; E Müller-Schweinitzer; R Waite
Journal:  Arzneimittelforschung       Date:  1975-10

6.  Measurement of residual glomerular filtration rate in the patient receiving repetitive hemodialysis.

Authors:  J Milutinovic; R E Cutler; P Hoover; B Meijsen; B H Scribner
Journal:  Kidney Int       Date:  1975-09       Impact factor: 10.612

7.  Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. A double-blind cross-over trial versus clonidine.

Authors:  W Kirch; A Distler
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-03
  7 in total
  5 in total

1.  Guanfacine produces differential effects in frontal cortex compared with striatum: assessed by phMRI BOLD contrast.

Authors:  Neil Easton; Yasmene B Shah; Fiona H Marshall; Kevin C Fone; Charles A Marsden
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

2.  Pharmacokinetics of guanfacine in patients undergoing haemodialysis.

Authors:  W Kirch; H Kohler; T Axthelm
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Oct-Dec       Impact factor: 2.441

Review 3.  Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of atenolol--a review.

Authors:  W Kirch; K G Görg
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982       Impact factor: 2.441

Review 5.  Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.

Authors:  Henry A Spiller; Hannah L Hays; Alfred Aleguas
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.